Adial Pharmaceuticals Net Income

Adial Pharmaceuticals (ADIL) currently reports a net income of $-58M as of June 2026. That compares with $-8.4M in the prior-year period — down 584.0% year over year. That is below the Healthcare sector average of $16B. Use the charts on this page to explore Adial Pharmaceuticals's net income history and peer comparisons.

Adial Pharmaceuticals's net income decreased from $-8.4M to $-58M — a 584.0% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Adial Pharmaceuticals's net income of $-58M is lower than the Healthcare sector average of $16B. That is roughly 100.4% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Adial Pharmaceuticals reported $-58M in net income as of June 2026. That compares with $-8.4M in the prior-year period — down 584.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current net income of $-58M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $16B. From there, open related valuation or income-statement pages for Adial Pharmaceuticals, and consider following ADIL for alerts when major investors trade the stock.